Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 53 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HCG Clear all

Conditions: HCG
Interventions: Human Chorionic Gonadotropin, Placebo, Low calorie diet; Drug · Other
Lead sponsor: Dr. Emma's Corporation; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Colts Neck, New Jersey

Conditions: Pregnancy of Unknown Location (PUL)
Interventions: at-home quantitative urine b-hCG test; Diagnostic Test
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Infertility
Interventions: HCG is introduced; Drug
Lead sponsor: Servy Massey Fertility Insititute; Other
Eligibility: 21 Years to 47 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Abortion in First Trimester
Interventions: Choice of follow-up option, Multi-level pregnancy test; Other · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy
Interventions: GE-145 (AN113111) Injection, Visipaque (iodixanol) Injection; Drug
Lead sponsor: GE Healthcare; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Breast Cancer, Colorectal Cancer, Pancreatic Cancer, Bladder Cancer, Ovarian Cancer
Interventions: CDX1307; Biological
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 3
States / cities: Detroit, Michigan • Durham, North Carolina • Huntersville, North Carolina

Conditions: Infertility, Female
Interventions: Low dose hCG; Other
Lead sponsor: Reproductive Medicine Associates of New Jersey; Other
Eligibility: 18 Years to 46 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Basking Ridge, New Jersey

Conditions: Trisomy 21
Interventions: Not listed
Lead sponsor: Roche Sequencing Solutions; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 18,955 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 26
States / cities: Tucson, Arizona • Oakland, California • Palo Alto, California + 20 more

Conditions: Endometrial Receptivity, Ovarian Hyperstimulation Syndrome
Interventions: GnRH agonist, hCG; Drug
Lead sponsor: UConn Health; Other
Eligibility: 21 Years to 33 Years · Female only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Acute Stroke
Interventions: Dual Growth Factor; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 21 Years to 85 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Orange, California

Conditions: Stroke
Interventions: human chorionic gonadotropin (hCG), then epoetin alfa (EPO), Saline Placebo; Drug
Lead sponsor: Stem Cell Therapeutics Corp.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Orange, California

Conditions: Medical Abortion
Interventions: Self-assessment: MLPT, Self-assessment: LSPT; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Infertility
Interventions: Bravelle(follicle stimulating hormone), Saline ( placebo); Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Pregnancy, Abortion Early
Interventions: Weekly high-sensitivity urine pregnancy tests; Diagnostic Test
Lead sponsor: University of Washington; Other
Eligibility: Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Atlanta, Georgia • Chevy Chase, Maryland • Renton, Washington

Conditions: Acute-graft-versus-host Disease
Interventions: Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 12 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Oligospermia, Azoospermia, Nonobstructive, Infertility
Interventions: isotretinoin, Human chorionic gonadotrophin (hCG); Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 50 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Pregnancy Detection
Interventions: Diagnostic Test; Device
Lead sponsor: NOWDiagnostics, Inc.; Industry
Eligibility: 14 Years and older · Female only
Enrollment: 892 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Los Angeles, California • Midland, Texas

Conditions: Infertility, Subfertility
Interventions: human chorionic gonadotropin (hCG), Placebo Comparator (for hCG); Drug
Lead sponsor: Michigan State University; Other
Eligibility: 18 Years to 34 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Ovarian Hyperstimulation Syndrome
Interventions: Leuprolide acetate; Drug
Lead sponsor: University of Connecticut; Other
Eligibility: 20 Years to 39 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Control Media Only, Study hCG and Media
Interventions: hCG at the Time of Embryo Transfer, Control; Other
Lead sponsor: Reproductive Medicine Associates of New Jersey; Other
Eligibility: 18 Years to 43 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Basking Ridge, New Jersey • Allentown, Pennsylvania

Conditions: Hypogonadism, Spinal Cord Injury
Interventions: Human chorionic gonadotropin (hCG), Luteinizing hormone releasing hormone (LHRH); Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Down Syndrome, Chromosome Abnormalities
Interventions: Ultrasound, Serum screen; Procedure
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 38,000 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 10
States / cities: Denver, Colorado • Boston, Massachusetts • Royal Oak, Michigan + 6 more

Conditions: Graft vs Host Disease
Interventions: Pregnyl®; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 76 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Medical Abortion
Interventions: serum BhCG follow-up, ultrasonographic follow-up; Other
Lead sponsor: Planned Parenthood League of Massachusetts; Other
Eligibility: 18 Years to 64 Years · Female only
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Muscle-Sparing Effect Of Human Chorionic Gonadotropin (hCG) During a Very Low Calorie Diet (VLCD)

MIRA CONNECT Study

Injection of Hormone to Enhance Implantation in Embryo Transfer After IVF

Choice of Modality of Follow up for Medication Abortion

Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)

A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)

Prospective Assessment of Impact of Personalized Dosing of Low-dose Human Chorionic Gonadotropin (hCG) on in Vitro Fertilization (IVF) Outcomes

Non-invasive Chromosomal Examination of Trisomy Study

Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation

Beta-hCG + Erythropoietin in Acute Stroke

Study of NTx®-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

Medical Abortion Self-Confirmation (MASC)

Concomitant Administration of FSH With HCG Improves Oocyte Maturation and Quality Double -Blinded Randomized Trial

Assessment of Early Pregnancy MAB Completion

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

Isotretinoin vs hCG for Male Infertility Due to Low or Absent Sperm

First To Know Pregnancy Test - Clinical Evaluation Protocol

Effect of hCG on Receptivity of the Human Endometrium

The Use of GnRH Agonist Trigger in the Prevention of OHSS

Intrauterine Human Chorionic Gonadotropin at the Time of Embryo Transfer

Provocative Testing Using LHRH and hCG of the Pituitary-Gonadal Axis in Persons With Spinal Cord Injury.

Down Syndrome - Comparison of Screening Methods in the 1st and 2nd Trimesters

Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD

Does Follow-up With Serum Beta Human Chorionic Gonadotropin (BhCG) Simplify Medical Abortion?